ReviewMedical oncology (Northwood, London, England)1996
Granulocyte-macrophage colony-stimulating factor and the immune system.
Review in Medical oncology (Northwood, London, England), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.PloS one · 2020Trial
- Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.British journal of cancer · 2010Trial
- NFL-TBS.40-63 Peptide Gold Complex Nanovector: A Novel Therapeutic Approach to Increase Anticancer Activity by Breakdown of Microtubules in Pancreatic Adenocarcinoma (PDAC).ACS pharmacology & translational science · 2022Article
- NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.Medical oncology (Northwood, London, England) · 2022Review
- Signatures of Selection for Environmental Adaptation and Zebu × Taurine Hybrid Fitness in East African Shorthorn Zebu.Frontiers in genetics · 2017Article
- Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination.Journal of virology · 2011Article
- Post-transcriptional Regulation of NK Cell Activation.Immune network · 2009Article
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.Cancer immunology, immunotherapy : CII · 2008Review
- Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.Clinical immunology (Orlando, Fla.) · 2008Article
- Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.Cancer science · 2008Article
- [Mini-organ cultures of human nasal mucosa. A model for eco-genotoxicological investigations].HNO · 2005Article
- Transgenic mice showing inflammation-inducible overexpression of granulocyte macrophage colony-stimulating factor.Clinical and diagnostic laboratory immunology · 2004Article
- Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa.Infection and immunity · 2003Article
- Staphylococcus aureus agr and sarA functions are required for invasive infection but not inflammatory responses in the lung.Infection and immunity · 2002Article
- Effects of granulocyte-macrophage colony stimulating factor (GM-CSF) in vivo on cytokine production and proliferation by spleen cells.Clinical and experimental immunology · 2001Article
- Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine.Gene therapy · 2001Article
- Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria.Infection and immunity · 2001Article
- New developments in autologous tumor cell vaccination therapy for renal cell carcinoma.Current oncology reports · 2000Article
- GM-CSF-deficient mice are susceptible to pulmonary group B streptococcal infection.The Journal of clinical investigation · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multifunctional cytokine currently used for the reversal of neutropenia associated with cytotoxic chemotherapy, bone marrow and haemopoietic stem cell transplantation. GM-CSF also modulates the function of differentiated white blood cells. In the context of local inflammatory responses, GM-CSF stimulates macrophages for antimicrobial and antitumor effects. GM-CSF further enhances healing and repair by its actions on fibroblasts and epidermal cells. GM-CSF is the pivotal mediator of the maturation and function of dendritic cells, the most important cell type for the induction of primary T cell immune responses. GM-CSF may enhance antibody dependent cellular cytotoxicity (ADCC) in several cell types, and the generation and cytotoxicity of natural killer (NK) cells. On this basis, GM-CSF may be useful for inducing or augmenting antibody responses to antimicrobial vaccines, to enhance killing of intracellular microorganisms, to accelerate epidermal and mucosal wound healing, and to stimulate protective immunity against tumors.
Indexed as
Identifiers
9106171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.